2013
Cost-effectiveness of novel first-line treatment regimens for tuberculosis
Owens JP, Fofana MO, Dowdy DW. Cost-effectiveness of novel first-line treatment regimens for tuberculosis. The International Journal Of Tuberculosis And Lung Disease 2013, 17: 590-596. PMID: 23575322, PMCID: PMC3844288, DOI: 10.5588/ijtld.12.0776.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsFirst-line treatmentStandard treatmentTotal disability-adjusted life yearsFailure/relapseShort-course regimensFirst-line regimensFirst-line drugsHigher drug costsHealth care perspectiveDrug pricesTB patientsActive tuberculosisNovel regimensPatient cohortDrug costsEqual efficacyRegimensLife yearsCare perspectiveTuberculosisRelapsePatientsTreatmentShort duration
2011
The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa
Walensky RP, Wood R, Fofana MO, Martinson NA, Losina E, April MD, Bassett IV, Morris BL, Freedberg KA, Paltiel AD. The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: 26-35. PMID: 21068674, PMCID: PMC3005842, DOI: 10.1097/qai.0b013e3181fb8f24.Peer-Reviewed Original ResearchConceptsVoluntary HIV screeningQuality-adjusted life yearsHIV screeningLife yearsHIV case detectionHIV testing costsTest acceptance rateIncremental cost-effectiveness ratioSubstantial clinical benefitIncidence/prevalenceOne-time screeningDirect medical costsLife expectancyQuality-adjusted life expectancyCost-effectiveness ratioAntiretroviral therapyAnnual incidenceClinical benefitHIV prevalenceClinical impactCase detectionMedical costsCare ratesHIVTest acceptance